SEC Tracker
Get the app

Edwards Lifesciences EW

Edwards Lifesciences reports strong Q3 growth

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. Q3 sales grew 10.5% to $1.72 billion
  2. TMTT sales grew 44.0% to $207 million
  3. Adjusted EPS of $0.80, up 19% versus prior year

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Edwards Lifesciences files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

The reading, claim by claim

  1. Under Item 2.02, it said it issued a press release setting out its financial results for the third quarter of 2026, furnished as Exhibit 99.1.
  2. Item 2.02 states that the information furnished, including Exhibit 99.1, shall not be deemed 'filed' for purposes of the Securities Exchange Act of 1934.
  3. Item 9.01 lists Exhibit 99.1, the press release dated November 4, 2026, and Exhibit 104, the cover page interactive data file.
  4. The filing is signed by Chief Financial Officer Theodora Mistras.
  5. The press release reports results for the quarter ended September 30, 2026.
  6. Q3 sales grew 10.5% to $1.72 billion, and constant currency sales grew 11.2%.
  7. Q3 TAVR sales grew 8.0% to $1.24 billion, and Q3 TMTT sales grew 44.0% to $207 million.
  8. Q3 EPS was $0.53, and adjusted EPS was $0.80.
  9. The release also lists 2026 outlook changes.
  10. TMTT sales guidance rises to $780 to $790 million from $760 to $780 million.
  11. Adjusted EPS guidance is now $2.97 to $3.05, from $2.95 to $3.05.

11 of 12 claims matched the filing text.

Not found in the filing text

  • Total company sales growth guidance rises to approximately 11.5% from 10% to 11%.

For perspective, checked against its own source

From the 10-Q for the quarter ended September 30, 2026

  • In its 10-Q for the quarter ended September 30, 2026, Edwards reported revenue of $1.7 billion and net income of $307.5 million.
  • That report gives a gross margin of 78.5%, an operating margin of 17.4% and a revenue change from a year earlier of +10.5%.

From the filing

Item 2.02. Results of Operations and Financial Condition.

On November 4, 2026, Edwards Lifesciences Corporation, a Delaware corporation ("Edwards"), issued a press release setting forth Edwards' financial results for the third quarter of 2026.1 A copy of the press release is furnished as Exhibit 99.1, and is incorporated herein by reference.1

The information furnished under this Item 2.02, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of the Securities Exchange Act of 1934, as amended.2

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

99.1 Press release, dated November 4, 2026, reporting Edwards' financial results for the third quarter of 2026.3

104 Cover Page Interactive Data File (embedded within the Inline XBRL document).3

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 4, 2026

EDWARDS LIFESCIENCES CORPORATION

By: /s/ Theodora Mistras4

Theodora Mistras

Chief Financial Officer4

Exhibit Index

Exhibit

Number Description

99.1 Press release, dated November 4 , 2026, reporting Edwards' financial results for the third quarter of 2026.

104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

Edwards Lifesciences Corporation

One Edwards Way · Irvine, CA USA · 92614

Phone: 949.250.2500 · www.edwards.com

FOR IMMEDIATE RELEASE

Media: Eric Endicott, media@edwards.com

Investors: Gerianne Sarte, investor_relations@edwards.com

EDWARDS LIFESCIENCES REPORTS THIRD QUARTER RESULTS

IRVINE, CA, November 4, 2026 — Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended September 30, 2026.5

Q3 Financial Highlights

• Q3 sales grew 10.5% to $1.72 billion 1 , constant currency 2 sales grew 11.2%6 • Q3 TAVR sales grew 8.0% to $1.24 billion 17 , constant currency 2 sales grew 8.8% • Q3 TMTT sales grew 44.0% to $207 million 1,37 , constant currency 2 sales grew 45.6% 3 • Q3 EPS of $0.53 1 ; adjusted 2 EPS of $0.80 1 which grew 19% versus prior year8

2026 Outlook9

• Increasing total company sales 2 growth guidance to approximately 11.5% from 10% to 11%9 • Increasing TAVR sales 2 growth guidance to 9.0% to 9.5% from 8% to 9% • Increasing TMTT sales guidance to $780 to $790 million from $760 to $780 million10 • Increasing adjusted EPS guidance to $2.97 t o $3.05 from $2.95 to $3.0511, gro wing 18% at m idpoint versus prior year

• 2026 performance and milestone achievements reinforce long-term durable growth

Recent Highlights

• PROGRESS trial marks turning point in the management of moderate AS

• Practice-changing data adding to Edwards' body of structural heart clinical evidence presented at TCT

• Final TAVR NCD represents important step toward expanding access to timely, high-quality care

• U.S. approval of PASCAL Precision for tricuspid repair expands access to differentiated therapy

• U.S. approval of PASCAL Ace with Capture Clarity simplifies mitral device placement

• European approval of SAPIEN M3 RESILIA brings most advanced tissue treatment to patients

• U.S. approval of AUTUS addresses lifelong needs of pediatric patients with congenital heart disease

"We delivered strong third-quarter growth of 11.2% which exceeded expectations, with broad-based performance across our businesses and regions, giving us the confidence to raise our full-year outlook," said Bernard Zovighian, CEO of Edwards Lifesciences. "Our focused structural heart strategy, coupled with disciplined execution, long-term investments in category-creating innovation, and commitment to science and technology advancements, enabled us to deliver significant progress for patients on several of our most important clinical, regulatory, policy and commercial priorities this quarter. As I reflect on 2026 so far, I am proud of what our teams have accomplished and how we are positioning Edwards for strong, sustainable growth over the long term."

Transcatheter Aortic Valve Replacement (TAVR)

In the third quarter, the company reported TAVR sales of $1.2 billion, which increased 8.0% compared to the prior year, or 8.8% on a constant currency basis. Edwards' growth rates were similar in the U.S. and outside of the U.S. Globally, procedural growth benefited from a heightened focus on TAVR and data supporting proactive disease management of severe aortic stenosis (AS). Exiting Q3, the company saw encouraging signs of procedure growth. After several quarters of modest share gains, Edwards is pleased with how its competitive position, supported by its differentiated SAPIEN platform, has contributed to year-to-date TAVR performance. Average selling prices were stable globally.

In the U.S., procedure growth continued to benefit from a heightened focus on TAVR therapy as the clinical community further incorporates into practice the meaningful evidence supporting proactive disease management. Edwards' competitive position in the U.S. was stable sequentially and increased modestly year-over-year, enabled by strong adoption of its SAPIEN 3 Ultra RESILIA platform. During the quarter, the Centers for Medicare & Medicaid Services (CMS) released the final, updated national coverage determination (NCD) for TAVR. The updated policy represents an important step toward improving and expanding timely, high-quality access to care while reinforcing the value of the multidisciplinary heart team.

Outside of the U.S., the company continues to see strong adoption of its SAPIEN technology. In Europe, updated ESC and EACTS guidelines are helping shape clinical discussions around earlier intervention and proactive disease management, further reinforcing the role of TAVR across a broader patient population. In Japan, Edwards was encouraged by the growth and continued adoption of its SAPIEN 3 Ultra RESILIA platform. Also in Japan, Edwards secured new and dedicated reimbursement for the SAPIEN 3 Ultra RESILIA platform, which recognizes the value of its innovation and helped contribute to Japan's strong performance in the quarter.

Transcatheter Mitral and Tricuspid Therapies (TMTT)

Third quarter TMTT sales of $207 million 3 increased 44.0% compared to the prior year, or 45.6% on a constant currency basis. Results were driven by the company's differentiated portfolio of repair and replacement therapies. Globally, mitral and tricuspid procedure volumes continued to grow in the double digits.

The value of the company's TMTT

Similar companies

Companies of similar size in SIC 3842 and related industry codes: the same peer list as the financial tables.

  1. Resmed RMD public float $34.9B, Dec 31, 2025
  2. Dexcom DXCM public float $34.2B, Jun 30, 2025
  3. GE HealthCare Technologies GEHC public float $34.0B, Jun 30, 2025
  4. Becton Dickinson BDX public float $65.5B, Mar 31, 2025, over 18 months old
  5. 3M MMM public float $81.1B, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.